Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Califf Continues Clinical Trial Reform Crusade With Confirmation Vote Pending

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA Commissioner nominee outlines ideas for improving clinical trials in written responses to senators' questions; HELP Committee to vote Jan. 12.

You may also be interested in...



Woodcock's Legacy: CDER Organizational Improvements

In interview with the Pink Sheet, Center for Drug Evaluation and Research director discusses her 30-year career, retirement speculation, and upcoming projects.

PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources

Growth of post-market surveillance system also may require more resources.

Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories

In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel